Biggest changeRefer to "Cost of Revenues – Industrial Operations " and "Operating Expenses" below for further discussion. • We recognized other patent portfolio expense of $162,000 in 2021 for settlement and contingency expenses. 31 Table of Contents • General and administrative expenses increased $17.0 million, from $35.7 million to $52.7 million in 2022, primarily due to higher parent company and Intellectual Property Operations costs including, parent company consulting and legal fees related to the Recapitalization Agreement and the Life Sciences Portfolio, severance expense, compensation expense for share-based awards, personnel costs and board fees, accounting fees, and $7.2 million from our Industrial Operations general and administrative costs and amortization expense.
Biggest changeRefer to "Energy Operations – Cost of Production" below for further discussion. • General and administrative expenses decreased $9.0 million, from $52.7 million to $43.7 million in 2023, primarily due to lower parent company and Intellectual Property Operations costs including, compensation expense for share-based awards, personnel costs, severance costs and our Industrial Operations general and administrative costs, offset partially by an increase in variable performance-based compensation costs and the addition of $264,000 expenses from our Energy Operations related to post-acquisition general and administrative costs from Benchmark for the period from November 13, 2023 through December 31, 2023.
For additional information regarding ARG's patent portfolio valuation estimates, refer to Note 2 to the consolidated financial statements. The Company did not record any long-lived asset, patent or other intangible asset impairment charges for the years ended December 31, 2022 and 2021. Goodwill asset impairment reviews include determining the estimated fair values of our reporting units.
For additional information regarding ARG's patent portfolio valuation estimates, refer to Note 2 to the consolidated financial statements. The Company did not record any long-lived asset, patent or other intangible asset impairment charges for the years ended December 31, 2023 and 2022. Goodwill asset impairment reviews include determining the estimated fair values of our reporting units.
Due to uncertainties related to our ability to utilize certain deferred tax assets in future periods, we have recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2022 and 2021. These assets primarily consist of foreign tax credits and net operating loss carryforwards.
Due to uncertainties related to our ability to utilize certain deferred tax assets in future periods, we have recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2023 and 2022. These assets primarily consist of foreign tax credits and net operating loss carryforwards.
The effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions used to estimate the effective tax rate, including factors such as expected utilization of net operating loss carryforwards, changes in or the interpretation of tax laws in jurisdictions where the Company conducts business, the Company’s expansion into new states or foreign countries, and the amount of valuation allowances against deferred tax assets.
The effective tax rate may be subject to fluctuations during the year as new information is obtained which may affect the assumptions used 45 Table of Contents to estimate the effective tax rate, including factors such as expected utilization of net operating loss carryforwards, changes in or the interpretation of tax laws in jurisdictions where the Company conducts business, the Company’s expansion into new states or foreign countries, and the amount of valuation allowances against deferred tax assets.
Any changes in the judgments, assumptions and estimates associated with our analysis of the need for a valuation allowance in any future periods could materially impact our financial position and results of operations in the periods in which those determinations are made. 41 Table of Contents Recent Accounting Pronouncements Refer to Note 2 to consolidated financial statements included elsewhere herein. 42 Table of Contents
Any changes in the judgments, assumptions and estimates associated with our analysis of the need for a valuation allowance in any future periods could materially impact our financial position and results of operations in the periods in which those determinations are made. Recent Accounting Pronouncements Refer to Note 2 to consolidated financial statements included elsewhere herein. 52 Table of Contents
During 2021, we acquired one new patent portfolio consisting of Wi-Fi 6 standard essential patents. In 2020, we acquired five new patent portfolios consisting of (i) flash memory technology, (ii) voice activation and control technology, (iii) wireless networks, (iv) internet search, advertising and cloud computing technology and (v) GPS navigation.
Dur ing 2021, we acquired one new patent portfolio consisting of Wi-Fi 6 standard essential patents. In 2020, we acquired five new patent portfolios consisting of (i) flash memory technology, (ii) voice activation and control technology, (iii) wireless networks, (iv) internet search, advertising and cloud computing technology and (v) GPS navigation.
To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statements of operations. Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and our valuation allowance.
To the extent we establish a valuation allowance or increase this allowance in a period, we must include an expense within the tax provision in the consolidated statements of operations. 51 Table of Contents Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and our valuation allowance.
Through our Patent Licensing, Enforcement and Technologies Business, operated under Acacia Research Group, LLC and its wholly-owned subsidiaries ("ARG"), we are a principal in the licensing and enforcement of patent portfolios, with our operating subsidiaries obtaining the rights in the patent portfolio or purchasing the patent portfolio outright.
Through our Patent Licensing, Enforcement and Technologies Business, operated under our wholly owned subsidiary, Acacia Research Group, LLC, and its wholly-owned subsidiaries (collectively, “ ARG ” ), we are a principal in the licensing and enforcement of patent portfolios, with our operating subsidiaries obtaining the rights in the patent portfolio or purchasing the patent portfolio outright.
In preparing these financial statements, we make assumptions, judgments and estimates that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations.
In preparing these financial statements, we make assumptions, judgments and estimates that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our 49 Table of Contents financial condition or results of operations.
We believe that of the significant accounting policies discussed in Note 2 to the consolidated financial statements included elsewhere herein, the following accounting policies require our most difficult, subjective or complex assumptions, judgments and estimates: • revenue recognition; • valuation of long-lived assets, goodwill and other intangible assets; • valuation of Series B Warrants; • valuation of embedded derivatives; and • accounting for income taxes.
We believe that of the significant accounting policies discussed in Note 2 to the consolidated financial statements included elsewhere herein, the following accounting policies require our most difficult, subjective or complex assumptions, judgments and estimates: • revenue recognition; • estimates of crude oil and natural gas reserves • valuation of long-lived assets, goodwill and other intangible assets; • valuation of Series B Warrants; • valuation of embedded derivatives; and • accounting for income taxes.
We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from 39 Table of Contents these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.
We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates and make changes accordingly.
The patents and patent rights acquired in 2021 and 2020 have estimated economic useful lives of approximately five years. Industrial Printing Solutions Our Printronix subsidiary is a worldwide leader in multi‐technology supply‐chain printing solutions for a variety of industries, including manufacturing, transportation and logistics, retail distribution, food and beverage distribution, and pharmaceutical distribution.
The patents and patent rights acquired in 2021 and 2020 have estimated economic useful lives of approximately five years. Industrial Operations Business 38 Table of Contents Our Printronix subsidiary is a worldwide leader in multi‐technology supply‐chain printing solutions for a variety of industries, including manufacturing, transportation and logistics, retail distribution, food and beverage distribution, and pharmaceutical distribution.
Operating Activities Intellectual Property Operations Our Intellectual Property Operations revenues historically have fluctuated quarterly, and can vary significantly period to period, based on a number of factors including the following: • the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee; • the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments; • fluctuations in the total number of agreements executed each period; • the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs; • the relative maturity of licensing programs during the applicable periods; • other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors; • the willingness of prospective licensees to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as such infringement cases approached a court determined trial date; and • fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above.
Operating Activities Intellectual Property Operations Our Intellectual Property Operations revenues historically have fluctuated quarterly, and can vary significantly period to period, based on a number of factors including the following: • the dollar amount of agreements executed each period, which can be driven by the nature and characteristics of the technology or technologies being licensed and the magnitude of infringement associated with a specific licensee; • the specific terms and conditions of agreements executed each period including the nature and characteristics of rights granted, and the periods of infringement or term of use contemplated by the respective payments; • fluctuations in the total number of agreements executed each period; • the number of, timing, results and uncertainties associated with patent licensing negotiations, mediations, patent infringement actions, trial dates and other enforcement proceedings relating to our patent licensing and enforcement programs; • the relative maturity of licensing programs during the applicable periods; • other external factors, including the periodic status or results of ongoing negotiations, the status or results of ongoing litigations and appeals, actual or perceived shifts in the regulatory environment, impact of unrelated patent related judicial proceedings and other macroeconomic factors; • the willingness of prospective licensees to settle significant patent infringement cases and pay reasonable license fees for the use of our patented technology, as such infringement cases approached a court determined trial date; and • fluctuations in overall patent portfolio related enforcement activities which are impacted by the portfolio intake challenges discussed above. 39 Table of Contents Our management does not attempt to manage for smooth sequential periodic growth in revenues from period to period, and therefore, periodic results can be uneven.
Due to the inherent subjectivity and uncertainty in forecasting future 40 Table of Contents cash flows and earnings over long periods of time, actual results may vary materially from the forecasts.
Due to the inherent subjectivity and uncertainty in forecasting future cash flows and earnings over long periods of time, actual results may vary materially from the forecasts.
Liquidity and Capital Resources General Our foreseeable material cash requirements as of December 31, 2022, are recognized as liabilities or generally are otherwise described in Note 11, "Commitments and Contingencies," to the consolidated financial statements included elsewhere herein.
Liquidity and Capital Resources General Our foreseeable material cash requirements as of December 31, 2023, are recognized as liabilities or generally are otherwise described in Note 13, "Commitments and Contingencies," to the consolidated financial statements included elsewhere herein.
We generate revenues and related cash flows from the granting of IP rights for the use of patented technologies that our operating subsidiaries control or own. We have established a proven track record of licensing and enforcement success with over 1,600 license agreements executed to date, across nearly 200 patent portfolio licensing and enforcement programs.
We generate revenues and related cash flows from the granting of IP rights for the use of patented technologies that our operating subsidiaries control or own. We have established a proven track record of licensing and enforcement success with over 1,600 license agreements executed as of December 31, 2023, across nearly 200 patent portfolio licensing and enforcement programs.
Our actual results could differ materially from those anticipated in these "forward-looking statements" as a result of various factors including the risks we discuss in Item 1A “Risk Factors,” and elsewhere herein.
Our actual results could differ materially from those anticipated in these “forward-looking statements” as a result of various factors including the risks we discuss in Item 1A “Risk Factors,” and elsewhere herein.
Patent Portfolio Intake One of the significant challenges in the intellectual property industry continues to be quality patent intake due to the challenges and complexity associated with the current patent environment. 27 Table of Contents During the year ended December 31, 2022, we did not acquire any new patent portfolios.
Patent Portfolio Intake One of the significant challenges in the intellectual property industry continues to be quality patent intake due to the challenges and complexity associated with the current patent environment. During the years ended December 31, 2023 and 2022, we did not acquire any new patent portfolios.
Acquisitions In October 2021, we consummated our first operating company in connection with our acquisition of Printronix. We acquired all of the outstanding stock of Printronix, for a cash purchase price of approximately $37.0 million, which included an initial $33.0 million cash payment and a $4.0 million working capital adjustment.
Acquisitions In October 2021, we consummated our first operating company acquisition in connection with our acquisition of Printronix. We acquired all of the outstanding stock of Printronix, for a cash purchase price of approximately $37.0 million, which included an initial $33.0 million cash payment and a $4.0 million working capital adjustment. The Company's consolidated financial statements include Printronix's consolidated operations.
Our results included an unrealized loss from the change in fair value of our equity securities as compared to an unrealized gain in the prior period, while realized gains from the sale of our equity securities increased, as compared to the prior period. These changes were derived from our Life Sciences Portfolio and trading securities portfolio.
Our results included an unrealized gain from the change in fair value of our equity securities as compared to an unrealized loss in the prior year, and included realized loss from the sale of our equity securities as compared to a realized gain in the prior year. These changes were derived from our Life Sciences Portfolio and trading securities portfolio.
Refer to Note 15 to the consolidated financial statements for additional information.
Refer to Note 17 to the consolidated financial statements for additional information.
The Company's goodwill balance relates to Printronix, which was acquired on October 7, 2021, refer to Note 1 to the consolidated financial statements for additional information. The Company did not record any goodwill impairment charges for the years ended December 31, 2022 and 2021.
The Company's goodwill balance relates to primarily Printronix, which was acquired on October 7, 2021, and Benchmark, which was acquired on November 13, 2023, refer to Notes 1 and 3 to the consolidated financial statements for additional information. The Company did not record any goodwill impairment charges for the years ended December 31, 2023 and 2022.
The net decrease was comprised of the change in total revenues described above and other changes in operating expenses and other income or expense as follows: • Inventor royalties increased $70,000, from $1.1 million to $1.2 million in 2022, primarily due to license agreement activity and related revenues generated with inventor royalty obligations.
The net increase was comprised of the change in total revenues described above and other changes in operating expenses and other income or expense as follows: • Inventor royalties decreased $187,000, from $1.2 million to $1.0 million in 2023, primarily due to license agreement activity and related revenues generated in 2023 with no inventor royalty obligations.
Refer to Item 1A “Risk Factors” for additional information regarding litigation and licensing expense risk.
Refer to Item 1A “Risk Factors” of this Annual Report for additional information regarding litigation and licensing expense risk.
Refer to " Equity Securities Investments " below for further discussion. • Unrealized gain from the Series A and Series B warrants and the embedded derivative fair value measurements was $13.1 million in 2022, as compared to an unrealized loss of $40.4 million in the prior year.
Refer to " Equity Securities Investments " below for a detailed discussion. • Unrealized gain from the Series B warrants and the embedded derivative fair value measurements was $8.2 million in 2023, as compared to an unrealized gain of $13.1 million from the Series A and Series B warrants and embedded derivative fair value measurements in the prior year.
Refer to " General and Administrative Expenses " below for further detail and discussion. • Compensation expense for share-based awards, included in general and administrative expenses above, increased $1.8 million, from $2.1 million to $3.8 million in 2022, primarily due to restricted stock and option grants issued to employees and the Board in 2022 and 2021, which includes a partial offset by forfeitures for terminated employees. • Unrealized loss from the change in fair value of our equity securities was $263.7 million in 2022, as compared to an unrealized gain of $87.5 million in the prior year.
Refer to " General and Administrative Expenses " below for further detail and discussion. • Compensation expense for share-based awards, included in general and administrative expenses above, decreased $523,000, from $3.8 million to $3.3 million in 2023, primarily due to forfeitures for terminated employees, which was partially offset by restricted stock and option grants issued to employees and the Board in 2023 and 2022. • Unrealized gain from the change in fair value of our equity securities was $31.4 million in 2023, as compared to an unrealized loss of $263.7 million in the prior year.
We are particularly attracted to complex situations, where value is not fully recognized in the public markets, where values of certain operations are masked by a diversified business mix, or where private ownership has not invested capital necessary to drive long-term value.
We are particularly attracted to complex situations where we believe value is not fully recognized, the value of certain operations are masked by a diversified business mix, or where private ownership has not invested the capital and/or resources necessary to support long-term value.
Our 2022 effective tax rates were lower than the U.S. federal statutory rate primarily due to expiration of foreign tax credits and changes in valuation allowance. Our 2021 effective tax rates were lower than the U.S. federal statutory rate primarily due to the change in valuation allowance, as well as non-deductible items.
Our 2023 effective tax rate was lower than the U.S. federal statutory rate primarily due to utilization of foreign tax credits, changes in valuation allowance, as well as non-deductible items. Our 2022 effective tax rate was lower than the U.S. federal statutory rate primarily due to the change in valuation allowance, as well as non-deductible items.
Refer to "Cost of Revenues – Intellectual Property Operations " below for further discussion. • Litigation and licensing expenses decreased $1.5 million, from $5.5 million to $4.0 million in 2022, primarily due to a net decrease in litigation support and third-party technical consulting expenses associated with ongoing litigation.
Refer to "Intellectual Property Operations – Cost of Revenues " below for further discussion. • Litigation and licensing expenses increased $6.8 million, from $4.0 million to $10.8 million in 2023, primarily due to a net increase in litigation support and third-party technical consulting expenses associated with ongoing litigation.
General and Administrative Expenses A summary of the main drivers of the change in general and administrative expenses is as follows: Years Ended December 31, 2022 vs. 2021 (In thousands) Personnel costs and board fees $ 1,391 Variable performance-based compensation costs (848) Other general and administrative costs 4,836 General and administrative costs - industrial operations 5,856 Amortization of industrial operations intangible assets 1,333 Compensation expense for share-based awards 1,767 Non-recurring employee severance costs 2,679 Total change in general and administrative expenses $ 17,014 General and administrative expenses include employee compensation and related personnel costs, including variable performance based compensation and compensation expense for share-based awards, office and facilities costs, legal and accounting professional fees, public relations, stock administration, business development, fixed asset depreciation, amortization of Industrial Operations intangible assets, state taxes based on gross receipts and other corporate costs.
General and Administrative Expenses A summary of the main drivers of the change in general and administrative expenses is as follows: Years Ended December 31, 2023 vs. 2022 (In thousands) Personnel costs and board fees $ (1,005) Variable performance-based compensation costs 1,047 Other general and administrative costs (3,772) General and administrative costs - industrial operations (1,264) General and administrative costs - energy operations 264 Compensation expense for share-based awards (523) Non-recurring employee severance costs (3,733) Total change in general and administrative expenses $ (8,986) General and administrative expenses include employee compensation and related personnel costs, including variable performance based compensation and compensation expense for share-based awards, office and facilities costs, legal and accounting professional fees, public relations, stock administration, business development, fixed asset depreciation, amortization of Industrial Operations intangible assets, state taxes based on gross receipts and other corporate costs.
At the closing of the Series B Warrants Exercise, the Company will pay to Starboard an aggregate amount of $66,000,000 (the “Recapitalization Payment”) representing a negotiated settlement of the foregone time value of the Series B Warrants and the Series A Preferred Stock (which amount will be paid through a reduction in the exercise price of the Series B Warrants).
At the closing of the Series B Warrants Exercise, the Company effectively paid to Starboard an aggregate amount of $66.0 million representing a negotiated settlement of the foregone time value of the Series B Warrants and the Series A Redeemable Convertible Preferred Stock (which amount was paid through a reduction in the exercise price of the Series B Warrants).
The decrease in variable performance-based compensation costs was primarily due to fluctuations in performance-based compensation accruals. The increases in other general and administrative costs, which relates to our parent company and Intellectual Property Operations business, were primarily due to parent company consulting and legal fees related to the Recapitalization Agreement and the Life Sciences Portfolio and higher accounting fees.
The increase in variable performance-based compensation costs was primarily due to fluctuations in performance-based compensation accruals. The decrease in other general and administrative costs, which relates to our parent company and Intellectual Property Operations business, were primarily due to lower legal fees.
Printronix is a leading manufacturer and distributor of industrial impact printers, also known as line matrix printers, and related consumables and services. The Printronix business serves a diverse group of customers that operate across healthcare, food and beverage, manufacturing and logistics, and other sectors. This mature technology is known for its ability to operate in hazardous environments.
The Printronix business serves a diverse group of customers that operate across healthcare, food and beverage, manufacturing and logistics, and other sectors. This mature technology is known for its ability to operate in hazardous environments.
We aim to operate a transactional platform through which we can initiate a strategic block position in public companies as a path to complete whole company acquisitions or strategic transactions that unlock value.
Through our public market activities, we aim to initiate strategic block positions in public companies as a path to complete whole company acquisitions or strategic transactions that unlock value.
Industrial Operations Refer to "Industrial Printing Solutions" above for information related to Printronix's operating activities.
Industrial Operations Refer to "Industrial Operations Business" above for information related to Printronix's operating activities. Energy Operations Refer to "Energy Operations Business" above for information related to Benchmark's operating activities.
The Company has recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2022 and 2021. Refer to Notes 2 and 15 to the consolidated financial statements elsewhere herein for additional income tax information. Inflation Historically, inflation has not had a significant impact on us or any of our subsidiaries.
The Company has recorded a partial valuation allowance against our net deferred tax assets as of December 31, 2023 and 2022. Refer to Notes 2 and 17 to the consolidated financial statements elsewhere herein for additional income tax information.
Patent Licensing and Enforcement Patent Litigation Trial Dates and Related Trials As of the date of this report, our operating subsidiaries have four pending patent infringement cases with scheduled trial dates in the next twelve months.
Patent Licensing and Enforcement Patent Litigation Trial Dates and Related Trials As of the date of this Annual Report, our Patent Licensing, Enforcement and Technologies Business has one pending patent infringement case with scheduled trial dates in the next twelve months.
The unrealized loss and gain were derived from our Life Sciences Portfolio and trading securities portfolio. The current period unrealized loss primarily relates to the reversal of prior period unrealized gains for Life Sciences Portfolio securities that were sold for a realized gain in 2022.
The unrealized gain and loss were derived from our Life Sciences Portfolio and trading securities portfolio. The prior year unrealized loss primarily relates to the reversal of unrealized gains previously recorded for shares sold during the year for realized gains.
Refer to periodic change explanations above. Refer to Notes 2 and 3 to the consolidated financial statements elsewhere herein for additional information regarding our investment in the Life Sciences Portfolio and other equity securities.
During the fourth quarter of 2022, Acacia fully exited its position in Oxford Nanopore. Refer to periodic change explanations above. Refer to Notes 2 and 4 to the consolidated financial statements elsewhere herein for additional information regarding our investment in the Life Sciences Portfolio and other equity securities.
Our facilities lease obligations, guarantees and certain contingent obligations are further described in Note 11 to the consolidated financial statements. Historically, we have not entered into off-balance sheet financing arrangements. At December 31, 2022, we had unrecognized tax benefits, as further described in Note 15 to the consolidated financial statements.
Historically, we have not entered into off-balance sheet financing arrangements. At December 31, 2023, we had unrecognized tax benefits, as further described in Note 17 to the consolidated financial statements.
Our management believes that our cash and cash equivalent balances, anticipated cash flows from operations and the transactions taken and contemplated to be taken in connection with the Recapitalization, and our availability of Senior Secured Notes will be sufficient to meet our cash requirements through at least twelve months from the date of this report and for the foreseeable future.
Our management believes that our cash and cash equivalent balances and cash flows from operations will be sufficient to meet our cash requirements through at least twelve months from the date of this Annual Report and for the foreseeable 46 Table of Contents future.
We have a strategic relationship with Starboard that has provided, and we expect will continue to provide, us with industry expertise, and operating partners and industry experts to evaluate potential acquisition opportunities and enhance the oversight and value creation of such businesses once acquired.
Relationship with Starboard Value, LP Our strategic relationship with Starboard provides us access to industry expertise, and operating partners and industry experts to evaluate potential acquisition opportunities and enhance the oversight and value creation of such businesses once acquired.
Cash Flows from Financing Activities Cash flows from financing activities included the following for the periods presented: Years Ended December 31, 2022 2021 (In thousands) Repurchase of common stock $ (50,988) $ (4,012) Issuance of Senior Secured Notes, net of lender fee — 115,000 Paydown of Senior Secured Notes (120,000) (50,000) Dividend on Series A Redeemable Convertible Preferred Stock (2,799) (1,452) Taxes paid related to net share settlement of share-based awards (1,600) — Proceeds from exercise of Series A warrants 9,250 — Proceeds from exercise of stock options — 202 Net cash (used in) provided by financing activities $ (166,137) $ 59,738 Cash outflows from financing activities for the year ended December 31, 2022 increased to $166.1 million, as compared to cash flow of $59.7 million in the prior year, primarily due to activity related to our Senior Secured Notes and our common stock repurchases (refer to Note 12).
Cash Flows from Financing Activities Cash flows from financing activities included the following for the periods presented: Years Ended December 31, 2023 2022 (In thousands) Repurchase of common stock $ — $ (50,988) Paydown of Revolving Credit Facility (7,700) — Paydown of Senior Secured Notes (60,000) (120,000) Dividend on Series A Redeemable Convertible Preferred Stock (1,400) (2,799) Taxes paid related to net share settlement of share-based awards (614) (1,600) Proceeds from Rights Offering 79,111 — Proceeds from exercise of Series A warrants — 9,250 Proceeds from exercise of Series B warrants 49,000 — Proceeds from exercise of stock options 235 — Net cash provided by (used in) financing activities $ 58,632 $ (166,137) Cash inflows from financing activities for the year ended December 31, 2023 increased to $58.6 million, as compared to cash outflow of $166.1 million in the prior year, primarily due to activity related to the Rights Offering and Concurrent Private Rights Offering.
These future opportunities can result in varying outcomes. Refer to Item 1A “Risk Factors — Risks Related to our Intellectual Property Business and Industry ” for additional information regarding patent litigation and related risks.
Refer to Item 1A “Risk Factors — Risks Related to our Intellectual Property Business and Industry ” of this Annual Report for additional information regarding patent litigation and related risks.
Refer to "Cost of Revenues – Intellectual Property Operations " below for further discussion. • Contingent legal fees decreased $9.6 million, from $12.1 million to $2.4 million in 2022, primarily due to the decrease in Intellectual Property Operations revenues described above.
Refer to "Intellectual Property Operations – Cost of Revenues " below for further discussion. 40 Table of Contents • Contingent legal fees increased $8.6 million, from $2.4 million to $11.0 million in 2023, primarily due to the change in Intellectual Property Operations revenues described above.
These rights were primarily granted on a perpetual basis, extending until the expiration of the underlying patents. Paid-up revenue decreased $55.8 million due to a decrease in the number of agreements executed and a decrease in the average revenue per agreement. Recurring revenue, that provides for quarterly sales-based license fees, decreased $738,000 from various on-going license arrangements.
These rights were primarily granted on a perpetual basis, extending until the expiration of the underlying patents. Paid-up revenue increased $70.0 million due to one patent portfolio that generated license revenue in the fourth quarter of 2023. Recurring revenue, that provides for quarterly sales-based license fees, decreased $399,000 from various on-going license arrangements.
In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material.
In such event, a court may issue monetary sanctions against us or our operating subsidiaries or award attorney’s fees and/or expenses to a defendant(s), which could be material. At December 31, 2023, our primary sources of liquidity are cash and cash equivalents on hand and cash generated from our operating activities.
Refer to " Equity Securities Investments " below for further discussion. • Realized gain from the sale of our equity securities increased $9.2 million, from $116.1 million to $125.3 million in 2022. The realized gains were derived from our Life Sciences Portfolio and trading securities portfolio.
Refer to " Equity Securities Investments " below for further discussion. • Realized loss from the sale of equity securities was $10.9 million in 2023, as compared to a realized gain of $125.3 million in the prior year. The realized gains and losses were similarly derived from the sales activity from our Life Sciences Portfolio and trading securities portfolio.
Scheduled trial dates, as promulgated by the respective court, merely provide an indication of when, in future periods, the trials may occur according to the court’s scheduling calendar at a specific point in time. A court may change previously scheduled trial dates.
Patent infringement trials are components of its overall patent licensing process and are one of many factors that contribute to possible future revenue generating opportunities. Scheduled trial dates, as promulgated by the respective court, merely provide an indication of when, in future periods, the trials may occur according to the court’s scheduling calendar at a specific point in time.
The fluctuations in cash receipts for the periods presented primarily reflects the corresponding fluctuations in revenues recognized during the same periods, as described above, and the related timing of payments received from licensees and customers.
The fluctuations in cash receipts for the periods presented primarily reflects the corresponding fluctuations in revenues recognized during the same periods, as described above, and the related timing of payments received from licensees and customers. Our reported cash used in operations for the year ended December 31, 2023 was $22.5 million, compared to $37.3 million in the prior year.
This acquisition was made at what we believe to be an attractive purchase price, and we are now supporting existing management in its execution of strategic partnerships to generate growth.
This acquisition was made at what we believe to be an attractive purchase price, and we are now supporting existing management in its initiative to reduce costs and operate more efficiently and in its execution of strategic partnerships to generate growth. For more information related to our Industrial Operations, refer to the section entitled “ Industrial Operations Business ” below.
Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues. Industrial Operations Printronix's cost of sales for the years ended December 31, 2022 and 2021 was $19.4 million and $7.4 million, respectively.
Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
Refer to Note 8 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Senior Secured Notes. • Interest income and other, net was $5.4 million in 2022, as compared to $501,000 in the comparable prior period, mainly due to an increase in dividend income from our cash equivalents and equity security investments.
Refer to Note 10 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Senior Secured Notes. 41 Table of Contents • Interest income and other, net was $15.5 million in 2023, as compared to $5.4 million in the prior year, mainly due to an increase in interest income from our cash equivalents, offset partially by an increase in the write off of the remaining limited unsecured notes of Adaptix Limited.
Refer to additional change explanations above. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our former investment in Veritone.
Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our cash and cash equivalents and investments in equity securities.
While insignificant to our consolidated enterprise, during the year ended December 31, 2022, our Printronix subsidiary experienced some inflation from higher freight costs and in the cost of raw materials than in previous years.
Inflation Historically, inflation has not had a significant impact on us or any of our subsidiaries. While insignificant to our consolidated enterprise, during the year ended December 31, 2023, our Printronix subsidiary experienced some inflation from higher cost of raw materials than in previous years due to higher electronic and electrical and metal components.
We expect to finance such acquisitions through cash on hand or by engaging in equity or debt financing.
Furthermore, we intend to grow our company by acquiring additional operating businesses and intellectual property assets. We expect to finance such acquisitions through cash on hand or by engaging in equity or debt financing.
Income Taxes Years Ended December 31, 2022 2021 $ Change % Change (In thousands, except percentage change values) Income tax benefit (expense) $ 16,211 $ (24,287) $ 40,498 (167 %) Effective tax rate (13) % 14 % n/a (27) % Our income tax benefit for the year ended December 31, 2022 primarily reflects the decrease in deferred tax liabilities attributable to the unrealized losses recorded, expiration of foreign tax credits and changes in the valuation allowance.
Our income tax benefit for the year ended December 31, 2022 primarily reflects the decrease in deferred tax liabilities attributable to the unrealized losses recorded, expiration of foreign tax credits and changes in the valuation allowance.
Refer to Note 8 to the consolidated financial statements elsewhere herein for additional information related to the Senior Secured Notes. On October 30, 2022, the Company entered into a Recapitalization Agreement with Starboard and the Investors. Refer to Note 8 to the consolidated financial statements elsewhere herein for additional information.
On October 30, 2022, the Company entered into a Recapitalization Agreement with Starboard and the Investors. On July 13, 2023, Starboard completed the Series B Warrants Exercise through a combination of a "Note Cancellation" and a "Limited Cash Exercise." Refer to Note 10 to the consolidated financial statements elsewhere herein for additional information.
The increase was primarily derived from our foreign cash accounts exposed to fluctuations in foreign currency exchange rates between the U.S. dollar and the British Pound. • Interest expense on Senior Secured Notes decreased $1.5 million, from $7.9 million to $6.4 million in 2022, due to decreased interest expense related to recent Note activity.
The gains and losses were primarily derived from our foreign cash accounts exposed to fluctuations in foreign currency exchange rates between the U.S. dollar and the British Pound. • Interest expense on Senior Secured Notes decreased $4.5 million, from $6.4 million to $1.9 million in 2023, due to the cancellation of the remaining $60.0 million aggregate principal amount outstanding of the Senior Secured Notes on July 13, 2023, pursuant to the Series B Warrants Exercise.
If we fail to obtain additional financing when needed, we may not be able to execute our business plans and our business, conducted by our operating subsidiaries, may suffer.
If we fail to obtain additional financing when needed, we may not be able to execute our business plans and our business, conducted by our operating subsidiaries, may suffer. Cash, Cash Equivalents and Investments Our consolidated cash, cash equivalents and equity securities totaled $403.2 million at December 31, 2023, compared to $349.4 million at December 31, 2022.
ARG executed 17 new license agreements during 2022, a decrease of six versus the comparable prior period, which contributed to Intellectual Property Operations revenues decreasing by $56.5 million. Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
ARG revenues increased due to one patent portfolio that generated license revenue in the fourth quarter of 2023, which contributed to Intellectual Property Operations revenues increasing by $69.6 million. Refer to “Investments in Patent Portfolios” above for additional information regarding the impact of portfolio acquisition trends on current and future licensing and enforcement related revenues.
Cash receipts from Printronix's customers totaled $40.5 million and $11.7 million for the year ended December 31, 2022 and the period from October 7, 2021 through December 31, 2021, respectively.
Cash receipts from Printronix's customers totaled $37.3 million and $40.5 million for the years ended December 31, 2023 and 2022, respectively. Cash receipts from Benchmark's customers totaled $1.8 million for the post acquisition period from November 13, 2023 through December 31, 2023.
Printronix's current deferred revenue increased to $1.2 million at December 31, 2022, compared to $1.1 million at December 31, 2021. 38 Table of Contents Cash Flows from Investing Activities Cash flows from investing activities were comprised of the following for the periods presented: Years Ended December 31, 2022 2021 (In thousands) Acquisition, net of cash acquired $ — $ (33,250) Patent acquisition (5,000) (21,000) Sale of investment at fair value — 3,591 Purchases of equity securities (112,142) (66,624) Sales of equity securities 273,934 154,784 Cash distributed for notes receivable — (4,021) Distributions received from equity investment in joint venture 28,404 2,362 Purchases of property and equipment (732) (91) Net cash provided by investing activities $ 184,464 $ 35,751 Cash flows from investing activities for the year ended December 31, 2022 increased to $184.5 million, as compared to cash flow of $35.8 million in the prior year, primarily due to net cash inflows from our Life Sciences Portfolio and trading securities portfolio equity securities transactions in 2022.
The increase is primarily due to change in accounts receivable, which is related to the timing of the cash receipts related to Intellectual Property Operations Business. 48 Table of Contents Cash Flows from Investing Activities Cash flows from investing activities were comprised of the following for the periods presented: Years Ended December 31, 2023 2022 (In thousands) Acquisition, net of cash acquired (Note 3) $ (9,409) $ — Cash reinvested 9,965 — Patent acquisition (6,000) (5,000) Purchases of equity securities (13,072) (112,142) Sales of equity securities 32,106 273,934 Distributions received from equity investment in joint venture 2,777 28,404 Purchases of property and equipment (189) (732) Net cash provided by investing activities $ 16,178 $ 184,464 Cash flows from investing activities for the year ended December 31, 2023 decreased to $16.2 million, as compared to cash flow of $184.5 million in the prior year, primarily due to net cash inflows from our Life Sciences Portfolio, trading securities portfolio equity securities transactions and Acacia's acquisition of Benchmark in 2023.
The costs associated with the forementioned obligations fluctuate period to period, based on the amount of revenues recognized each period, the terms and conditions of revenue agreements executed each period and the mix of specific patent portfolios, with varying economic terms and conditions, generating revenues each period.
The costs associated with the forementioned obligations fluctuate period to period, based on the amount of revenues recognized each period, the terms and conditions of revenue agreements executed each period and the mix of specific patent portfolios, with varying economic terms and conditions, generating revenues each period. 42 Table of Contents Litigation and licensing expenses include patent-related litigation, enforcement and prosecution costs incurred by law firms and external patent attorneys engaged on either an hourly basis or a contingent fee basis.
Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding our cash and cash equivalents and investments in equity securities. 32 Table of Contents Revenues Intellectual Property Operations ARG's revenue activity for the periods presented included the following: Years Ended December 31, 2022 2021 $ Change % Change (In thousands, except percentage change values and count totals) Paid-up license revenue agreements $ 17,788 $ 73,585 $ (55,797) (76 %) Recurring license revenue agreements 1,720 2,458 (738) (30 %) Total revenues $ 19,508 $ 76,043 $ (56,535) (74 %) New license agreements executed 17 23 (6) (26 %) Licensing and enforcement programs generating revenues 8 9 (1) (11 %) Licensing and enforcement programs with initial revenues — 4 (4) (100 %) New patent portfolios — 1 (1) (100 %) For the periods presented above, the majority of the revenue agreements executed provided for the payment of one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technology owned by our operating subsidiaries.
Intellectual Property Operations Revenues ARG's revenue activity for the periods presented included the following: Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values and count totals) Paid-up license revenue agreements $ 87,835 $ 17,788 $ 70,047 394 % Recurring license revenue agreements 1,321 1,720 (399) (23 %) Total revenues $ 89,156 $ 19,508 $ 69,648 357 % New license agreements executed 16 17 (1) (6 %) Licensing and enforcement programs generating revenues 7 8 (1) (13 %) For the periods presented above, the majority of the revenue agreements executed during the relevant period provided for the payment of one-time, paid-up license fees in consideration for the grant of certain IP Rights for patented technology owned by our operating subsidiaries.
Working Capital Our working capital related to cash flows from operating activities at December 31, 2022 decreased to $15.1 million, compared to $4.3 million at December 31, 2021, which was comprised of the changes discussed below. Accounts receivable decreased to $8.2 million at December 31, 2022, compared to $9.5 million at December 31, 2021.
Working Capital Our working capital related to cash flows from operating activities at December 31, 2023 increased to $87.0 million, compared to $15.1 million at December 31, 2022, which was comprised of the changes in assets and liabilities presented above.
Operating Expenses Years Ended December 31, 2022 2021 $ Change % Change (In thousands, except percentage change values) Engineering and development expenses - industrial operations $ 626 $ 200 $ 426 213 % Sales and marketing expenses - industrial operations 8,621 1,538 7,083 461 % General and administrative costs - intellectual property operations 5,428 6,177 (749) (12 %) General and administrative costs - industrial operations 9,986 2,797 7,189 257 % Parent general and administrative expenses 37,266 26,692 10,574 40 % Total general and administrative expenses 52,680 35,666 17,014 48 % Total $ 61,927 $ 37,404 $ 24,523 66 % The operating expenses table above includes the Company's general and administrative expenses by operation and Printronix's engineering and development expenses and sales and marketing expenses.
Operating Expenses Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Engineering and development expenses - industrial operations $ 735 $ 626 $ 109 17 % Sales and marketing expenses - industrial operations 6,908 8,621 (1,713) (20 %) General and administrative costs - intellectual property operations 7,402 5,428 1,974 36 % General and administrative costs - industrial operations 8,722 9,986 (1,264) (13 %) General and administrative costs - energy operations 264 — 264 n/a Parent general and administrative expenses 27,306 37,266 (9,960) (27 %) Total general and administrative expenses 43,694 52,680 (8,986) (17 %) Total $ 51,337 $ 61,927 $ (10,590) (17 %) The operating expenses table above includes the Company's general and administrative expenses by operation and Printronix's engineering and development expenses and sales and marketing expenses.
Other Income/Expense Equity Securities Investments Years Ended December 31, 2022 2021 $ Change % Change (In thousands, except percentage change values) Change in fair value of equity securities $ (263,695) $ 87,527 $ (351,222) (401 %) Gain on sale of equity securities 125,318 116,129 9,189 8 % Earnings on equity investment in joint venture 42,531 3,530 39,001 1,105 % Net realized and unrealized (loss) gain (95,846) 207,186 (303,032) (146 %) Change in fair value of investment — (2,752) 2,752 (100 %) Gain on sale of investment — 3,591 (3,591) (100 %) Total net realized and unrealized (loss) gain $ (95,846) $ 208,025 $ (303,871) (146 %) 35 Table of Contents Our equity securities investments, including the Life Sciences Portfolio and trading securities portfolio, are recorded at fair value at each balance sheet date.
Other Income/Expense Equity Securities Investments Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Change in fair value of equity securities $ 31,423 $ (263,695) $ 295,118 (112 %) (Loss) gain on sale of equity securities (10,930) 125,318 (136,248) (109 %) Earnings on equity investment in joint venture 4,167 42,531 (38,364) (90 %) Total net realized and unrealized gain (loss) $ 24,660 $ (95,846) $ 120,506 (126 %) Our equity securities investments, including the Life Sciences Portfolio and trading securities portfolio, are recorded at fair value at each balance sheet date.
In addition to the foregoing, we will be required to make the Recapitalization Payment at the closing of the Series B Warrants Exercise. Cash requirements are generally derived from our operating and investing activities including expenditures for working capital (discussed below), human capital, business development, investments in equity securities and intellectual property, and business combinations.
Cash requirements are generally derived from our operating and investing activities including expenditures for working capital (discussed below), human capital, business development, investments in equity securities and intellectual property, and business combinations. Our facilities lease obligations, guarantees and certain contingent obligations are further described in Note 13 to the consolidated financial statements.
In fact, courts often reschedule trial dates for various reasons that are unrelated to the underlying patent assets and typically for reasons that are beyond our control. While scheduled trial dates provide an indication of the timing of possible future revenue generating opportunities for us, the trials themselves and the immediately preceding periods represent the possible future revenue generating opportunities.
A court may change previously scheduled trial dates. In fact, courts often reschedule trial dates for various reasons that are unrelated to the underlying patent assets and typically for reasons that are beyond the control of our Patent Licensing, Enforcement and Technologies Business.
While Printronix inventory costs have 36 Table of Contents been impacted by these inflationary pressures, up to this point Printronix has generally been able to adjust selling prices in response to these higher costs.
While Printronix inventory costs have been impacted by these inflationary pressures, up to this point Printronix has generally been able to adjust selling prices in response to these higher costs. Printronix have also implemented cost rationalization measures to combat the rising cost that is driven by inflation and currency pressures. Additionally, our Energy Operations Business may experience inflation.
Refer to Note 8 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Securities. • Loss on foreign currency exchange increased $3.2 million, from $89,000 to $3.3 million in 2022.
Refer to Notes 10 and 11 to the consolidated financial statements elsewhere herein for additional information regarding the Starboard Securities and fair value measurements. • Gain on foreign currency exchange was $53,000 in 2023, as compared to a loss on foreign currency exchange of $3.3 million in the prior year.
The decrease was offset by the additional net revenues contributed from Printronix of $27.7 million. Refer to "Revenues" below for further detailed discussion. Loss before income taxes was $127.2 million for the year ended December 31, 2022, as compared to income of $174.7 million in the prior year.
Income before income taxes was $67.4 million for the year ended December 31, 2023, as compared to loss of $127.2 million in the prior year.
As of December 31, 2022, we have generated gross licensing revenue of approximately $1.7 billion, and have returned $849.2 million to our patent partners. 25 Table of Contents For more information related to our Intellectual Property Operations, refer to additional detailed patent business discussion below. Industrial Operations In October 2021, we consummated our first operating company acquisition of Printronix.
For more information related to our Intellectual Property Operations, refer to additional detailed patent business discussion below. Industrial Operations In October 2021, we consummated our first operating company acquisition of Printronix. Printronix is a leading manufacturer and distributor of industrial impact printers, also known as line matrix printers, and related consumables and services.
In June 2022, in connection with the submission to the European Medicines Agency, on a consolidated basis, we were due an additional milestone payment in the amount of $1.8 million. Our portion of that milestone payment was received in July 2022. During 2022, we recorded consolidated earnings on equity investment of $42.5 million, including the two milestones and accrued interest.
During 2022, we recorded consolidated earnings on equity investment of $42.5 million, including two milestones and accrued interest that were due in 2022. Refer to Note 4 to the consolidated financial statements elsewhere herein for additional information.
Refer to “Industrial Printing Solutions” above for additional information related to Printronix's operating activities. 33 Table of Contents Cost of Revenues Intellectual Property Operations Years Ended December 31, 2022 2021 $ Change % Change (In thousands, except percentage change values) Inventor royalties $ 1,212 $ 1,142 $ 70 6 % Contingent legal fees 2,444 12,074 (9,630) (80 %) Litigation and licensing expenses 3,970 5,462 (1,492) (27 %) Amortization of patents 10,403 9,851 552 6 % Other patent portfolio expense — 162 (162) (100 %) Total $ 18,029 $ 28,691 $ (10,662) (37 %) Refer to detailed change explanations above for the year ended December 31, 2022 cost of revenues from our Intellectual Property Operations.
Cost of Revenues Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Inventor royalties $ 1,025 $ 1,212 $ (187) (15 %) Contingent legal fees 10,998 2,444 8,554 350 % Litigation and licensing expenses 10,771 3,970 6,801 171 % Amortization of patents 11,370 10,403 967 9 % Total $ 34,164 $ 18,029 $ 16,135 89 % Refer to detailed change explanations above for the year ended December 31, 2023 and 2022 regarding cost of revenues for our Intellectual Property Operations.
Refer to Note 9 to the consolidated financial statements for detailed information related to this fair value measurement. Of the assumptions used in the as-converted model, discount rate changes would have the most significant impact on the fair value.
Of the assumptions used in the as-converted model, discount rate changes had the most significant impact on the fair value. As of December 31, 2023, the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock is zero because it is no longer outstanding. Refer to Note 10 to the consolidated financial statements for more information.
Printronix's cost of sales figures include the full year ended December 31, 2022 compared to an approximate three month period ended December 31, 2021 following our acquisition of Printronix. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding Printronix's cost of sales.
The decrease in Printronix's cost of revenues for the year ended December 31, 2023 is due to change in revenue described above. Refer to Note 2 to the consolidated financial statements elsewhere herein for additional information regarding Printronix's cost of sales.
Summary of Results of Operations Years Ended December 31, 2022 2021 $ Change % Change (In thousands, except percentage change values) Total revenues $ 59,223 $ 88,047 $ (28,824) (33 %) Total costs and expenses 99,315 73,502 25,813 35 % Operating (loss) income (40,092) 14,545 (54,637) (376 %) Total other (expense) income (87,058) 160,107 (247,165) (154 %) (Loss) income before income taxes (127,150) 174,652 (301,802) (173 %) Income tax benefit (expense) 16,211 (24,287) 40,498 (167 %) Net (loss) income attributable to Acacia Research Corporation (125,065) 149,197 (274,262) (184 %) Results of Operations - year ended December 31, 2022 compared with the year ended December 31, 2021 Total revenues decreased $28.8 million to $59.2 million for the year ended December 31, 2022, as compared to $88.0 million for the year ended December 31, 2021, due to a decrease in our Intellectual Property Operations revenues.
Summary of Results of Operations Years Ended December 31, 2023 2022 $ Change % Change (In thousands, except percentage change values) Total revenues $ 125,102 $ 59,223 $ 65,879 111 % Total costs and expenses 104,166 99,315 4,851 5 % Operating income (loss) 20,936 (40,092) 61,028 (152 %) Total other income (expense) 46,490 (87,058) 133,548 (153 %) Income (loss) before income taxes 67,426 (127,150) 194,576 (153 %) Income tax benefit 1,504 16,211 (14,707) (91 %) Net income (loss) attributable to Acacia Research Corporation 67,060 (125,065) 192,125 (154 %) Results of Operations - year ended December 31, 2023 compared with the year ended December 31, 2022 Total revenues increased $65.9 million to $125.1 million for the year ended December 31, 2023, as compared to $59.2 million for the year ended December 31, 2022 , primarily due to an increase in our Intellectual Property Operations revenues partially offset by a decrease in Industrial Operations revenues.
Valuation of Embedded Derivatives Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument. An as-converted value is currently used to estimate the fair value of the embedded derivative in the Series A Redeemable Convertible Preferred Stock.
As of December 31, 2023, the fair value of the Series B Warrants is zero. Refer to Note 10 to the consolidated financial statements for more information. Valuation of Embedded Derivatives Embedded derivatives that are required to be bifurcated from their host contract are valued separately from the host instrument.